MedTrace Logo

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

NCT01806337 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-03-07

No results posted yet for this study

Summary

Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation

Conditions

  • Peripheral T-Cell Lymphoma

Interventions

DRUG

Alemtuzumab

Consolidation after CHOP induction

Sponsors & Collaborators

  • University of Göttingen

    lead OTHER

Principal Investigators

  • Lorenz Truemper · German High Grade Non Hodgkin´s Lymphoma Study Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-07-31
Completion
2011-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806337 on ClinicalTrials.gov